Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.64 |
| ▸ | MAPT | P10636 | 7/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Urea SCHEMBL4776814 | 0.97 | LMNA (0.60) | LMNAMAPTSMN1; SMN2KDM4EGAA | |
| SCHEMBL4781259 | 0.85 | SCD (0.53) | LMNAMAPTSMN1; SMN2GAAMEN1 | |
| SCHEMBL3651090 | 0.84 | ROCK1 (0.47) | RAB9AMAPK1 | |
| SCHEMBL354643 | 0.84 | L3MBTL1 (0.59) | LMNAMAPTSMN1; SMN2KDM4EGAA | |
| SCHEMBL353373 | 0.83 | ROCK1 (0.47) | MAPTSMN1; SMN2MEN1KMT2AMAPK1 | |
| SCHEMBL4726379 | 0.83 | TSHR (0.51) | SMN1; SMN2MAPK1 | |
| SCHEMBL4727779 | 0.83 | MAPT (0.64) | LMNAMAPTSMN1; SMN2KDM4EGAA | |
| SCHEMBL4780046 | 0.83 | TSHR (0.46) | LMNAMAPTSMN1; SMN2KDM4EGAA | |
| SCHEMBL353214 | 0.83 | ROCK1 (0.48) | MAPTSMN1; SMN2MEN1KMT2AMAPK1 | |
| SCHEMBL353663 | 0.83 | KMT2A (0.51) | SMN1; SMN2KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716320-B2 | Antibacteriall heterocyclic ureas | REPLIDYNE, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20080207703-A1 | Antibacterial heterocyclic ureas | REPLIDYNE, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| WO-2008011191-A1 | ANTIBACTERIAL HETEROCYCLIC UREAS | REPLIDYNE, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207703-A1 | Antibacterial heterocyclic ureas | UMPS, UROD, UGP2 | LMNA 3271/4885MAPT 2119/4885SMN1; SMN2 4077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.